Breaking News, Collaborations & Alliances

Ultragenyx, KHK in KRN23 Development Pact

Kyowa Hakko Kirin to manufacture and supply for clinical, commercial use

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Ultragenyx Pharmaceutical has entered into a collaboration and license agreement with Kyowa Hakko Kirin Co., Ltd. (KHK), to develop and commercialize KRN23, a recombinant fully human monoclonal IgG1 antibody intended to treat X-linked hypophosphatemia (XLH). KHK is currently completing a Phase I/II study in adults with XLH in the U.S. and Canada. The two companies plan to initiate a pediatric XLH program in 2014. XLH is a rare metabolic bone disorder caused by excessive loss of phosphate in the ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters